Soleno Therapeutics Faces Class Action Lawsuit Deadline

Investors have until May 5, 2026 to join lawsuit over alleged securities fraud

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Kahn Swick & Foti, LLC (KSF) has notified investors in Soleno Therapeutics, Inc. (Nasdaq: SLNO) of a class action securities lawsuit. The lawsuit seeks to recover losses on behalf of investors who were allegedly adversely affected by securities fraud between March 26, 2025 and November 4, 2025. Soleno investors have until May 5, 2026 to request to be appointed as lead plaintiff in the case.

Why it matters

This lawsuit highlights concerns about Soleno Therapeutics' disclosures regarding the safety and commercial viability of its only commercial product, DCCR, which is intended to treat hyperphagia in individuals with Prader-Willi syndrome. The allegations suggest Soleno may have minimized or mischaracterized potential safety issues, which could impact the drug's commercial prospects.

The details

According to the complaint, Soleno and certain executives are accused of failing to disclose material information during the class period, including: (i) the Phase 3 clinical trial program for DCCR systematically minimized, mischaracterized, and/or failed to disclose substantial evidence of potential safety concerns, such as indications of excessive fluid retention; (ii) the administration of DCCR posed materially greater safety risks than disclosed; and (iii) DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant adverse events after launch.

  • The class period is from March 26, 2025 to November 4, 2025.
  • Investors have until May 5, 2026 to request to be appointed as lead plaintiff in the case.

The players

Kahn Swick & Foti, LLC (KSF)

A boutique securities litigation law firm, ranked among the top 10 plaintiff law firms nationally based on total settlement value.

Charles C. Foti, Jr.

A KSF partner and former Attorney General of Louisiana.

Soleno Therapeutics, Inc.

A biopharmaceutical company developing DCCR, a treatment for hyperphagia in individuals with Prader-Willi syndrome.

Got photos? Submit your photos here. ›

What they’re saying

“Soleno investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.”

— Lewis Kahn, Managing Partner, Kahn Swick & Foti, LLC

What’s next

The judge in the case will decide on May 5, 2026 whether to appoint a lead plaintiff for the class action lawsuit against Soleno Therapeutics.

The takeaway

This lawsuit underscores the importance of pharmaceutical companies fully disclosing potential safety issues and risks associated with their drug candidates, as investors rely on this information to make informed decisions. The outcome of this case could have broader implications for the industry's transparency and accountability.